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ABSTRACT 
 
Background 
In 1995 the Tucson Children’s Respiratory Study (TCRS) identified clinically distinct phenotypes 
amongst early wheezers; the Avon Longitudinal Study of Parents And Children (ALSPAC) has 
recently re-examined these.  
 
Objectives 
To validate statistically derived ALSPAC phenotypes in the Southampton Women’s Survey (SWS) 
using infant and 6 year lung function, and allergic sensitisation at 1, 3 and 6 years, comparing these 
with TCRS phenotypes.  
 
Methods 
Complete 6 year follow-up data were available for 926 children, selected from  1973 infants born to 
12,579 women characterised pre-conception. 95 children had V’maxFRC and FEV0.4 measured age 
5-14 weeks using rapid compression/raised volume techniques. At 6 years we performed spirometry 
(n=791), fractional exhaled nitric oxide (FeNO, n=589) and methacholine challenge (n=234). Skin 
prick testing was performed at 12m, 3 and 6 years (n=1494, 1255, 699, respectively).  Using wheeze 
status questionnaire data at 6m, 12m, 2, 3 and 6 years we classified children into TCRS (never, 
transient early, persistent, late-onset) and ALSPAC based groups (never, early, transient, 
intermediate-onset, late-onset, persistent).   
 
Results 
Amongst ALSPAC groups, persistent and late-onset wheeze were associated with atopy at 3 and 6 
years, whilst intermediate-onset wheeze showed earlier atopic association at 1 year; all three were 
associated with FeNO at 6 years.  Persistent wheezers had lower infant (V’maxFRC p<0.05) and 6 
  
year lung function (FEV1, FEV1/FVC and FEF25-75, p<0.05), whilst late and intermediate-onset 
wheezers showed no lung function deficits.  Transient wheezers were non-atopic but showed 
persistent lung function deficits (V’maxFRC in infancy, FEV1 and FEF25-75 at 6 years, all p<0.05). 
Those who wheezed only in the first year (early phenotype) showed no lung function deficits.  No 
associations were seen with 6 years bronchial hyper-responsiveness or infancy FEV0.4.  
 
Conclusion 
SWS cohort data validates the statistically derived ALSPAC 6-class model. In particular, lung 
function and atopy successfully differentiate persistent, late-onset and intermediate-onset wheeze, 
whilst the Tucson ‘transient early’ wheeze phenotype can be sub-classified into groups that reflect 
early lung function.   Since the 4-class model fails to adequately differentiate phenotypes based on 
lung function and atopy, we propose that strong consideration be given to using the 6-class paradigm 
for longitudinal outcome work in wheezing with onset in early life. 
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INTRODUCTION 
 
Wheezing in infancy is common, however only a small proportion of these children will continue to 
wheeze into later childhood and beyond.  A number of studies have attempted to classify wheezing 
pre-school children into different phenotypes in order to assist  investigation of the pathways of 
asthma development.  The Tucson Children’s Respiratory Study (TCRS) published the first 
classification according to wheezing status up to 6 years of age1.  TCRS characterised children into 4 
groups, namely never wheezed, transient early wheeze, late wheeze and persistent wheeze;  
persistent and late-onset wheeze were associated with atopy, however transient early wheeze was 
not, as confirmed by further studies using this classification 2–5.   TCRS found persisting lung 
function deficits in those with transient wheeze, suggesting this was a phenomenon of small airways, 
with resolution of wheeze once airway calibre improves with growth, albeit without returning to 
normal1.  Whilst TCRS found that persistent wheezers did not have lung function deficits at birth, the 
Copenhagen Prospective Studies on Asthma and Childhood (COPSAC) cohort of at-risk children did 
find diminished lung function shortly after birth in those with asthma at 7 years6 and the authors 
hypothesized that perhaps TCRS had been underpowered to find this statistical difference.  Likewise, 
Turner et al found lung function deficits that preceded the development of asthma 7.  A cohort from 
Perth, Australia performed longitudinal lung function testing, comparing VmaxFRC at birth and 
FEF25-75 at 4-6 years and 11 years.  They found that transient wheezers (wheeze at 0-3 years) had the 
best lung function of all groups at birth, but this diminished over time with reference to other groups, 
supporting the idea that transient wheeze is associated with ongoing lung function deficits beyond 
the symptomatic period.  Development of late and persistent wheeze has been associated with 
reduced airway function interacting with atopic sensitisation, immune dysregulation and airway 
remodelling, in line with the classical view of asthma pathogenesis8–11.  It is possible that persistent 
wheezers represent an overlap between these theories of transient wheeze and more typical asthma 
pathogenesis with later resolution of wheeze by puberty in those who are not atopic4. 
  
 
The Tucson phenotype classification does not, however, fully describe the heterogeneity amongst 
wheezing children and attempts have been made to reclassify these phenotypes.  The Avon 
Longitudinal Study of Parents And Children (ALSPAC) used longitudinal latent class analysis 
(LLCA) to redefine the wheezing phenotypes purely on statistical grounds, independent from any 
preconceived bias of the clinician.  Amongst 6265 children followed-up to 6 years of age they 
identified six classes of pre-school wheeze; never/infrequent, transient early, prolonged early, 
intermediate onset, late onset and persistent 12.  They then replicated the process with 2810 children 
from the Prevention of Infant Asthma and Mite Allergy (PIAMA) cohort and 5760 from ALSPAC 
up to 8 years of age13.  The replication identified 5 classes of wheezing children; never, transient 
early, intermediate onset, late onset and persistent.  The intermediate onset, late onset and persistent 
phenotypes were strongly associated with atopy, with the strongest association seen amongst the 
intermediate-onset phenotype.  All wheezing groups showed poorer lung function at 8 years, 
including transient early wheezers who were, by definition, no longer wheezing by this time.  The 
transient early wheezers did not, however, show greater bronchial hyper-responsiveness (BHR) 
compared to those who never wheezed.  These findings suggest there is a distinct intermediate-onset 
phenotype not captured in the TCRS classification and reinforces the suggestion that transient early 
wheezers have ongoing diminished lung function without persisting symptoms of reactive airways.  
It is this latter group that may be at increased risk of chronic obstructive pulmonary disease (COPD) 
in later life owing to continued poor lung function14 15.  A recent application of latent class growth 
analysis, which differs slightly from LLCA, in the Columbia Children’s Centre for Environmental 
Health (CCEH) cohort of African-American and Latino children identified 4 classes that were 
similar to those in the TCRS study16.  Spycher et al also used LLCA in 1650 UK children, 
identifying 3 phenotypes of wheeze and 2 phenotypes of cough17.   
 
  
We hypothesised that the statistically derived ALSPAC 6-class model could be validated using  
longitudinal lung function and atopic sensitisation data from the first 6 years of life.  
  
 
 
METHODS 
Participants were mother-child pairs from the Southampton Women’s Survey; a cohort study with 
the objective, among others, of studying early life environmental influences on child growth and 
development, including respiratory disease and asthma in childhood18.  During the period 1998-2002, 
12,579 women aged 20-34 were recruited through their GP surgeries prior to conception.   There 
were 1973 births before the end of 2003. Those born before 35 weeks and/or twins were excluded 
from the study and only one child per SWS mother was included.  As previously described19 a subset 
of 150 infants born to the SWS women had lung function measured at 5-14 weeks postnatally, with 
95 of these having a complete set of data to 6 years.  Child follow-ups were conducted at 6 months 
(n=1896), 12 months (n=1840), 2 years (n=1735), 3 years (n=1640) and 6 years (n=940) through 
home visits or attendance at clinic.  The 6-year follow-up was performed during 2006-2010 and of 
the 1523 babies born between February 2000 and June 2003, 940 had questionnaire data from a 
home-visit and 791 had spirometry performed. Figure 1shows the numbers at each follow-up stage 
and the numbers who had lung function/skin prick testing.  Parental consent was obtained and ethics 
approval was granted by the Southampton and South West Hampshire Local Research Ethics 
Committee (LREC Number 276/97, 307/97, 089/99, 125/98 and 06/Q1702/104).  
 
Atopy 
Atopy was defined as any allergen response ≥ 3 mm against cat, dog, house dust mite 
(Dermatophagoides pteronyssinus), grass pollens, egg and milk allergens (Hollister-Stier, Spokane, 
WA) at ages 1 (n=1494) and 3 years (n=1255).  At 6 year follow-up (n=699), tree pollen was added 
(ALK Abelló Hørsholm, Denmark).  Readings were considered valid only in the presence of 
appropriate positive and negative control responses. 
 
  
Airway inflammation 
Exhaled nitric oxide (FeNO) was measured with a NIOX® chemiluminescence analyser (Aerocrine, 
Sweden) at a controlled expiration of 50ml/sec, by trained research nurses. The technique used was 
in line with the ERS/ATS recommendations20 and a mean value was calculated from three readings 
where possible.  FeNO data were normalised using an inverse square root transformation then 
standardised as a z-score. The sign of the values was reversed so that high untransformed FeNO 
values gave rise to high standardised scores. 
 
Allocation to wheeze phenotype groups 
The ISAAC core questionnaire wheezing module was delivered by research nurses21. Mothers were 
asked at each visit whether their child had experienced ‘episodes of chestiness associated with 
wheezing or whistling in his/her chest in the last 12 months’. Using wheeze data collected in the first 
year, at 2/3 years, and at 6 years old, the children were grouped into both the Tucson[1]; never, 
transient early, late, persistent groups, and ALSPAC based phenotypes13; never, early, transient, 
intermediate-onset, late-onset, and persistent wheeze.  Our ‘early’ and ‘transient’ groups were so 
named in order to differentiate them from the Tucson ‘transient early’ group and be roughly 
equivalent to  the ALSPAC ‘transient early’ and ‘prolonged transient’ groups12.  Table 1 shows how 
the children were classified into the wheezing phenotypes using the questionnaire data from 6m, 
12m, 2 years, 3 years and 6 years, and how our naming of groups corresponds to the ALSPAC 
phenotypes.  Children who wheezed in the first year and at 6 years but not in between were classified 
as persistent wheezers, in line with the ALSPAC/PIAMA LLCA allocations 13, however we 
acknowledge that these could be children who are a combination of the early and late-onset groups. 
 
Lung function 
  
In Infancy: As previously described19 infant lung function measurements were obtained during quiet 
sleep augmented by oral chloral hydrate (75-100mg/kg).  V’maxFRC was measured using rapid 
thoracic compression (RTC) during tidal breathing using an inflatable jacket and a leak-free 
facemask with Fleisch pneumatachograph (Dynasciences, Blue Bell, CA). RTC from a raised 
volume manoeuvre was used to calculate FEV0.4.  Data were collected in
 RASP software (Physiologic 
Ltd, Newbury, Berks, UK), with SQUEEZE software (Paul Dixon, London, UK) used to analyse the 
flow-volume curves and calculate FEV0.4. V’maxFRC and FEV0.4 were corrected for age at test but 
not for size19. 
 
At age 6 years: Spirometry was performed according to ATS/ERS guidelines20 but without noseclips.  
Experienced research nurses used a portable Koko spirometer and incentive software (KoKo version 
4; PDS Instrumentation; Louisville, USA) to record flow-volume loops.  FEV1, FEV1/FVC and 
FEF25-75 were corrected for height and gender, and expressed as percent predicted
22. 
 
Bronchial hyper-responsiveness (BHR) testing was performed according to ATS/ERS guidelines20 
using dosimeter administered methacholine (Koko; PDS Instrumentation; Louisville, USA) via an 
air-driven nebuliser (Sidestream®; Respironics, UK).  Methacholine doses ranged from 0.06 mg/ml 
to 16 mg/ml with termination at either the upper concentration or a 20% fall in FEV1.  Data were 
transformed using the formula Log.slope=100/[regression slope of FEV1 drop and log10(cumulative 
methacholine dose) + 10] in order to remove negative values and produce a normal distribution of 
the variable, with a lower value indicating greater responsiveness. 
 
Statistical Analysis 
Using STATA/SE 11.0, Poisson regression with robust variance was performed for atopic 
sensitisation outcomes23 giving the relative risk of atopy for each wheeze group at 1,3 and 6 years of 
  
age compared to those who never wheezed..  Linear regression was used for lung function outcomes, 
within which the following were assessed for potential confounding and included in the analysis if 
significantly correlated with the outcome and exposure; maternal asthma, smoking in pregnancy, 
smoke exposure in 1st year and 6th year of life, gestation, birth weight, birth weight z score (adjusted 
for gestation), sex, parity, maternal atopy, pets in the home, breastfeeding duration, social class, 
maternal education and month of birth.  This is in line with recent published recommendations for 
confounders in studies of childhood asthma24. The prevalence of the potential confounders for each 
of the ALSPAC and TCRS groups can be found in supplementary table 5 and 6.  Infant lung 
function, BHR and FeNO required log transformation to normalise and therefore they are presented 
as ratios of geometric means, which  provides consistency with the presentation of the ALSPAC 
data13. 
 
  
 
RESULTS 
Study population 
A total of 1840 (92.6%) children were seen at 1 year, 1735 (87.3%) at 2 years, 1640 (82.5%) at 3 
years and 940 (47.3%) at 6 year follow up (Figure 1). Children were more likely to have complete 
follow-up to 6 years if they were higher social class, had more highly educated parents, or were 
exposed to lower rates of smoking, as shown in supplementary table 1. There were no important 
differences in participants with spirometry in the 6-year follow-up versus those without and those 
with infant lung function versus those without (supplementary tables 2 and 3). The differences 
between those with follow-up and those without were included in our analysis as potential 
confounders (tables E4, E5 and E6). Table 2 shows the number of children in each phenotype who 
contributed spirometry, BHR, FeNO and skin test results data.  There were small numbers with 
infant lung function data in the intermediate-onset (n=4), late-onset (n=1) and persistent groups 
(n=5).  This was also true for BHR testing; intermediate n=17, late n=4 and persistent n=17.   
 
Wheeze phenotypes in SWS 
Using the Tucson and ALSPAC phenotypes, this SWS cohort  had 417 TCRS early transient 
wheezers (161 ALSPAC early and 256 ALSPAC transient) and 116 TCRS persistent wheezers (57 
ALSPAC intermediate-onset and 59 ALSPAC persistent) with 20 late-onset wheezers (same 
definition in ALSPAC and TCRS) (Figure 2).  
 
Lung function in infancy and childhood 
Lower infant lung function (V’maxFRC) was seen in ALSPAC and TCRS transient groups (p<0.05) 
and in the ALSPAC persistent (p<0.05) but not the TCRS persistent wheeze groups (Table 3).  No 
association was seen between infant FEV0.4 and any phenotype.   
  
The ALSPAC transient group showed statistically  lower lung function persisting to 6 years with a 
mean FEF25-75 of 95.1% predicted and FEV1 of 100.3% predicted (both p<0.05) versus 101.0% and 
103.1% respectively for the never wheezed group (table 3 and figures 3 and 4) .  The ALSPAC 
persistent group showed significantly lower 6 year FEF25-75 (mean 84.9%, p<0.001), FEV1 (97.3%, 
p<0.05) and FEV1/FVC (95.5%, p<0.05) whilst the TCRS persistent group also showed significantly 
lower in FEF25-75 (89.5%, P<0.001), FEV1 (99.0%) and FEV1/FVC (97.1%, all p<0.05).  The TCRS 
transient early group (including both ALSPAC early and transient groups) showed only reduced 
FEF25-75 at 6 years (96.7%, p<0.05).  Intermediate-onset and late-onset groups had similar lung 
function in infancy and at 6 years to the non-wheeze group.   
No associations were seen between BHR and any of the wheeze phenotypes.  Infant and 6 year lung 
function parameters were converted to z scores to enable tracking over time (figures 3a and 3b).  
When compared to others in our cohort, persistent wheezers’ z scores for our lung function 
parameters remain below all other groups.  Although the transient wheeze group are below the other 
groups (except persistent) in infancy, there is some improvement by age 6 relative to other wheezing 
groups.  They do, however remain below intermediate and late-onset groups despite the fact these 
two groups are now symptomatic and transient wheezers are not.   
 
 
Atopy in infancy and childhood 
None of the groups that had ceased wheezing by 6 years of age showed an increased risk of atopy at 
1, 3 or 6 years of age (table 4, figure 3).  Intermediate-onset wheezers showed an increased risk for 
atopy at all ages with relative risks of 3.3, 3.0 and 2.9 at 1, 3 and 6 years (all p<0.001), however late-
onset and persistent wheezers did not show an increased risk of atopy until 3 years of age (late - RR 
2.5 at 3 and 6 years, p<0.05, persistent - RR 2.4 and 2.0 at 3 and 6 years respectively, p<0.05).  
These RR are shown across the three ages in figure 3c. TCRS groups show a different pattern (table 
  
4). TCRS persistent wheeze showed an increased risk for atopy at all ages (RR 2.6 at 1yr, p<0.05, 
3.2 at 3yr and 2.6 at 6yrs, both p<0.001).  It should be noted that the TCRS persistent group would 
include the ALSPAC intermediate-onset wheezers that showed atopic sensitisation at all ages.   
 
Exhaled nitric oxide showed the same pattern of association as atopy at 6 years, being significantly 
associated with intermediate, late and persistent wheeze (all p<0.001) and significantly associated 
with atopy at 6 years in all children (p<0.001) (table 4). 
 
 
 
  
 
DISCUSSION 
The ALSPAC phenotypes 12 which were statistically derived based on symptoms, have successfully 
been validated using longitudinal lung function and atopic sensitisation data from the SWS cohort.  
This study, which included measurements not available within ALSPAC including infant lung 
function, FeNO at 6 years and 1 year atopy data, not only confirms that these phenotypes are real, 
but also provide insight into the underlying pathophysiology of each phenotype.    In particular, 
among those who are transient early wheezers, there appear to be physiologic differences between 
those who wheeze only in the first year and those who wheeze beyond the first year but have stopped 
wheezing by age 6. . Atopy was manifested quite early (by age 1) in subjects with intermediate onset 
wheeze, and by age 3 in those with late onset and persistent disease.  This lends further weight to the 
existence of separate late and intermediate-onset phenotypes and supports the hypothesis that 
persistent wheeze is an interplay between diminished lung function from birth and development of 
atopic sensitisation4 25. 
 
ALSPAC did not have FeNO data12, and our data have been able to show that wheeze at 6 years is 
not only associated with skin sensitisation but also with FeNO which is an indirect estimate of lower 
airway eosinophilic inflammation.  We have also shown that those who wheeze only in the first year 
of life appear distinct from other ‘transient’ wheezing groups, in that they show no lung function 
deficits in infancy or childhood and are perhaps similar to children in the never/infrequent wheeze 
group. 
 
In keeping with previous studies1 6 we  found that, when compared to children who have never 
wheezed, children with transient wheeze outside the first year are more likely to have persistently 
lower lung function even when symptoms have resolved. In contrast to the ALSPAC/PIAMA 13 and 
TCRS studies 1, the intermediate onset and late onset groups did not show significantly diminished 
  
lung function at 6 years compared to those who never wheeze.  It may be that greater numbers in 
these previous studies gave the power to detect small differences.  
 
It is widely accepted that transient early wheeze may be related to small airways 1, with improvement 
in wheeze as the child grows; however the pathogenesis is clearly more complex than this.  By 
separating the TCRS ‘transient early’ wheeze into ALSPAC ‘early’ (wheeze only in the first year) 
and ‘transient’ wheeze, differing associations were seen.  Early wheeze was not associated with 
diminished lung function or atopy, whilst the remainder of the transient wheezers showed diminished 
infant lung function (V’maxFRC) with persistence of these deficits up to 6 years (FEF25-75 and 
FEV1), at which time they were, by definition, asymptomatic. This is in keeping with the theory that 
transient wheeze is a product of reduced airway calibre that improves with age, such that children are 
no longer symptomatic but still have minor deficits in lung function.  Since persistent wheeze was 
not significantly associated with atopy at 1 year, this group may reflect a larger group of those with 
diminished lung function at birth that either cease to wheeze with growth (transient wheeze), have 
such diminished airway function that they fail to grow out of wheeze by 6 years (persistent non-
atopic wheeze) or develop atopic sensitisation that leads to persistent wheezing at 6 years (classical 
asthma).  It is possible that the ‘early’ wheezers have normal airways but an altered immune 
response to early viral infections that manifests as wheeze in the first year of life but improves as the 
immune system matures.  Since there was no significant difference in month of birth between the 
early group and the never wheezers or transient wheezers (data not shown), this does not simply 
reflect a seasonal effect of increased respiratory tract infections.  ALSPAC had classified children 
into a never/infrequent group 12 and our ‘early’ phenotype may correspond  more closely to this 
group, differentiating them from those who wheeze as a result of poor lung function and possibly 
reflecting a difference between bronchiolitis and viral-induced wheeze.  It is possible that the 
PIAMA LLCA analysis, which found a 5-class model to be optimal, had included these children 
  
within the never/infrequent group 13 and that our infant lung function data allowed identification of 
this extra class. The existence of this early group suggests that many of those who wheeze only in the 
first year of life do not do so as a result of significantly altered lung function.  This is in contrast to 
the theory suggested by Young et al who found that those who wheezed only in the first year of life 
had impaired lung function that resolved by 12m of age, whereas wheezing  through the first 2 years 
or in year 2 only was associated with persisting lung function deficits 11  
 
Our findings differ from ALSPAC/PIAMA as they found that all wheeze groups had significantly 
lower FEV1 at 8 years, whereas our intermediate and late groups did not show any significant 
difference from those who never wheezed.  This is most likely a reflection of the greater power in 
their studies and may also be why we did not show lung function deficits in the intermediate/late 
groups prior to the onset of wheeze, as previously suggested by the Aberdeen cohort 7 and COPSAC 
6.   Like the Perth cohort26, we found significantly reduced lung function in persistent wheezers both 
shortly after birth and at 6 years, but, unlike them, we found transient wheezers had diminished lung 
function shortly after birth as well.  We had the benefit of greater numbers in this wheeze group and, 
in line with the original TCRS infant lung function findings, our results likely reflect a significant 
difference in lung function at birth in transient wheezers.  Our findings that wheeze at school age was 
related to atopic sensitisation reinforces the findings of the German Multicentre Allergy Study 
(MAS), a birth cohort of 1314 healthy children, who found that persistence of wheezing through 
school years was related to development of atopy4.   
 
Strengths of this study are its infant lung function data, exhaled nitric oxide measurements and 
longitudinal atopic sensitisation data.  In particular, other cohorts have not included 1 year allergic 
sensitisation data.  Together, these data allow tracking of lung function and onset of atopy in relation 
to different wheeze phenotypes. A particular limitation of our study is the small numbers of children 
  
who had infant lung function and were wheezing at 6 years of age.  This lack of power may explain 
the absence of association between wheeze phenotypes and FEV0.4 in infancy (figure 3).  Similarly, 
there was a surprising lack of significant association with bronchial hyper-responsiveness at 6 years 
in children who were wheezing at 6 years. Again, lack of power is likely to be an issue as there were 
few children with BHR data in the intermediate (n=17), late (n=4) and persistent groups (n=17).  A 
planned meta-analysis of cohort data may overcome this problem.  As with most cohort studies of 
this type, there was a tendency for children of higher social class to attend follow-up; however we 
controlled for associated confounders (maternal smoking in pregnancy and during childhood, 
education and social class) in our analysis.  There were also differences between SWS and ALSPAC 
in wheezing time points used to classify the phenotypes with ALSPAC having data from 6m, 12m, 
18m 30m, 42m, 54m, 69m and 81m.  Rather than map our follow-up time points to these, we used 
the phenotype tracking figure that arose from their analysis and fitted our data to this graph12. Also, 
the 6 year lung function outcomes showed lung function that was statistically significantly lower in 
transient and persistent wheezers, however when expressed as percent predicted they are still within 
the expected normal range.  This means that the differences are potentially important on a population 
level but may not be clinically significant in the individuals.   
 
Many studies have attempted to identify risk factors for asthma/wheeze including fetal/postnatal 
growth parameters27 28, genetics29–33 and infant lung function7 26 34, with varying results. It is only by 
understanding the wheeze phenotypes that these relationships can be better elucidated and the 
diluting effects of grouping wheeze together in a small number of categories can be overcome.  
Table 3 shows how some significant associations are lost by analysing the children according to the 
broader Tucson phenotypes including failure to delineate the intermediate-onset group, failure to 
show infant lung function deficits in the persistent group and lack of diminished FEV1 at 6 years in 
the transient wheezers.  There is now good evidence that COPD and all-cause mortality in later life is 
  
related to airway function in childhood14 15 35 36 and this may be related to wheeze phenotype37.  Since 
infant lung function is impractical in most wheezing children, it is wheeze phenotype, particularly 
our transient wheeze group, that may provide information about later risk of asthma/COPD and risk 
of mortality from a wide range of causes. 
 
In conclusion, using longitudinal lung function and atopic sensitisation data, the SWS cohort has not 
only validated the statistically derived ALSPAC phenotypes of childhood wheeze, but has also 
provided insights to the underlying pathophysiology. Our findings confirm the existence of an 
‘intermediate-onset’ phenotype that is similar to late-onset wheeze but has earlier atopic 
sensitisation. The SWS cohort demonstrates the utility of separating the ‘transient early’ wheeze 
group, by considering those who wheeze in their first year only as a separate group..   We suggest 
that future research should focus on a 6-class model of early childhood wheeze.  Further work is 
needed to investigate whether the group of children who only wheeze in the first year of life reflect a 
separate phenotype or can be considered alongside those who never wheeze and thus a 5-class model 
may be appropriate class model of early childhood wheeze. 
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Figure Legends 
Figure 1. Diagram showing numbers in follow-up groups at each age and number who had skin prick testing and 
lung function measurements. 
 
Figure 2. Venn diagram showing distribution of children amongst Tucson groups (black circle) and ALSPAC groups 
(grey circles)  
 
Figure 3. Graph showing tracking of internal z scores for each ALSPAC phenotype for a) maximal flow at 
functional residual capacity (V’maxFRC) in infancy and forced expiratory flow at 25-75% vital capacity (FEF25-
75) at 6 years of age, b) forced expiratory volume in 0.4 seconds (FEV0.4) in infancy and forced expiratory volume 
in 1 second (FEV1) at 6 years of age and c) tracking of relative risk (RR) of atopy at 1, 3 and 6 years. 
